Geriatrics

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

Older patients benefit greater from LDL-cholesterol lowering medications.

Life expectancy rates were lower in patients with IBD when compared to a healthy control group.

Just 2% of observed older men to experience an indicative fracture received a diagnosis and treatment for osteoporosis over a four-year period.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

A younger baseline age and more injections during the first year of treatment was linked to better long-term outcomes.

Venetoclax in combination with azacitidine was shown to prolong survival and increase chance of remission.

Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.

ELP Pharma readying plans to continue to study the drug in a phase 3 trial.

History of syncope was present in 17% of the Parkinson group who had an altered blood pressure regulation upon standing and in 10% of those without.

SFChT in treatment-naïve eyes was positively associated with eGFR and diabetic retinopathy grade.

The treatment could also be used for Alzheimer disease and mid-stage Huntington disease for patients who suffer from greater cognitive deficits.

Those who slept more than 10 hours or less than 4 hours per night declined faster than those who slept about 7 hours per night.

Sumifilam could be the first Alzheimer treatment to improve several biomarkers.

More than half of the eyes observed in the study displayed collapse of the associated druse or drusenoid PED.

Current therapies focus on relief of symptoms, but there is still an unmet need to address and target the molecular defects of hypertrophic cardiomyopathy.

Problems using inhalers correctly is an ongoing issue for both pediatric and adult patients.

Countries, including the USA, have shown a stagnation or a small increase of deaths linked to NCDs.

The risk of developing fibrosis and macular atrophy increased based on which quartile of foveal center point thickness standard deviation an individual falls in.

The majority of older adults participating in the study expressed outrage at what they deemed to be an inadequate government response to the pandemic.

Investigators find study drug was well-tolerated with no new safety concerns.

The degree of photoreceptor degeneration outside of regions of retinal pigment epithelium atrophy varied substantially between eyes with AMD.

REGENXBIO also announced the scheduling of a phase 2 trial testing RGX-314 for wet AMD.

The risk of depression or clinically relevant depressive symptoms did not significantly differ between a group taking Vitamin D and a group taking a placebo.

In a comparison with manual human grading, investigators find machine learning model produced no statically significant differences in Dice coefficients.

A team of researchers have added 3 new modifiable risk factors to a list of 9 known factors that increase the risk of developing dementia.

An expert in Alzheimer disease describes some of the struggles dementia patients might be going through during the COVID-19 pandemic.

Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.

A new study has great implications for equitable access to primary care for older adults during the pandemic.

In a pair of studies, 42% of patients and care partners reported having no current treatment.